Request a Rep
Request a Rep

Consider the Full Impact of Symptom Burden for Patients With Obstructive HCM When Choosing Treatment

Obstructive HCM can affect more than the heart—symptoms can take a toll on day-to-day activities1

Patients with symptomatic oHCM may present with chest pain, fatigue, exertional dyspnea, palpitations, dizziness, and syncope.2 Symptom progression can be gradual — patients may be doing worse than they realize by adapting their daily routine to manage their condition.2-5 These adaptations can result in patients living according to their limitations and also make recognition of symptoms more difficult.1,4 Ultimately, their decreased physical activity and anxiety over the condition can have a negative influence on a patient’s quality of life.1

Because HCM is estimated to be underdiagnosed* there may be more people with the condition than suspected.6 Currently, the estimated prevalence of HCM ranges between 1 in 200 to 1 in 500 people in the general population.7,8 The majority of HCM cases are obstructive and among these patients, 66% are symptomatic.9 When patients are diagnosed it may be as late as young adulthood, or in mid-life, (median age at diagnosis, 45.8 years, SHaRe Registry) when the disease has progressed.10

This can result in serious complications such as NYHA Class III/IV heart failure (~43%), atrial fibrillation (18-28%), stroke or other thromboembolism (~6%), and rarely, sudden cardiac death (<1%/year).11-13 Obstructive HCM can even progress while patients are on treatment which can also contribute to these complications.14

HCM=hypertrophic cardiomyopathy; oHCM=obstructive HCM.

  • *Estimated undiagnosed range is calculated using the prevalence range of 1:200 to 1:500, the estimated US population (334,668,850 in April 2023), and the estimated diagnosed population (~100,000) based on 2013 ICD-9 claims data.6
  • The 2015 Semsarian publication identified that the prevalence of HCM gene carriers could be as high as 1:200.7
  • The CARDIA study (published in 1995) was a multicenter, US-population-based echocardiography study of 4111 subjects (aged 23-35) that identified the prevalence of HCM as 1:500 people in the general population.6

When Dani was diagnosed with symptomatic obstructive HCM, she was first prescribed an oral medication. When her symptoms and obstruction didn’t improve she eventually needed open-heart surgery, a myectomy.

Her symptoms did improve initially but within a matter of months, Dani was symptomatic again, and her obstruction had returned. How would you counsel a patient like Dani?

Dani was compensated for
her time.

CAMZYOS (mavacamten) Patient Dani
HCP Monitoring Patient Icon

Without your help, patients may overlook the impact that obstructive HCM has had on their lives5

HCP Monitoring Patient Icon

Because some people adapt their lifestyle to symptomatic obstructive HCM, ask patients or their care partners about their limitations of activity to get a complete picture of disease severity4,5

  • How is symptomatic obstructive HCM limiting them?
  • What activities are they cutting back on or stopping?
  • How often do you experience palpitations, dizziness, or chest pain?
  • What do they want and expect out of treatment?

AHA/ACC guidelines on HCM recommend shared decision-making between
the healthcare provider and patient to manage their condition2

ACC=American College of Cardiology; AHA=American Heart Association.

You can provide patients the possibility of symptom reduction and improved function, regardless of where they are in their journey with obstructive HCM2,15

Current treatments for symptomatic obstructive HCM

Pills Icon


The role of guideline-recommended treatment options is that of symptom management. Due to limited evidence from randomized controlled trials, management is often based on nonrandomized or limited data or on expert opinion.

Target Icon


Uniquely targets the source of obstructive HCM to work differently from pharmacological therapies traditionally used first-line. Studied with and without background therapy in 2 phase 3 trials.

Scalpel Icon


Guideline-recommended septal reduction therapy for patients whose symptoms are not relieved by pharmacological therapy.

  • §CAMZYOS is an allosteric and reversible inhibitor selective for cardiac myosin that helps to modulate the number of myosin heads in the off state. This reduces the number of myosin-actin cross-bridges that form.15

Consider the next step—complement conventional therapy with CAMZYOS15

See how CAMZYOS works >

This website is best viewed
using the horizontal display
on your tablet device.

This website is best viewed
using the vertical display
on your mobile device.


  1. Zaiser E, Sehnert AJ, Duenas A, Saberi S, Brookes E, Reaney M. Patient experiences with hypertrophic cardiomyopathy: a conceptual model of symptoms and impacts on quality of life. J Patient Rep Outcomes. 2020;4(1):102.
  2. Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2020;142(25):e533-e631.
  3. Naidu SS, ed. Hypertrophic Cardiomyopathy. London, Eng: Springer-Verlag; 2015.
  4. Jacoby DL, DePasquale EC, McKenna WJ. Hypertrophic cardiomyopathy: diagnosis, risk stratification and treatment. CMAJ. 2013;185(2):127-134.
  5. Borsari W, Davis L, Meiers E, Salberg L, Barbara McDonough. Living with hypertrophic cardiomyopathy: a patient’s perspective. Future Cardiol. 2022;18(1):43-50. doi:10.2217/fca-2021-0091
  6. Maron MS, Hellawell JL, Lucove JC, Farzaneh-Far R, Olivotto I. Occurrence of clinically diagnosed hypertrophic cardiomyopathy in the United States. Am J Cardiol. 2016;117(10):1651-1654.
  7. Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA study. Circulation. 1995;92(4):785-789.
  8. Semsarian C, Ingles J, Maron MS, Maron BJ. New perspectives on the prevalence of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2015;65(12):1249-1254.
  9. Data on file. BMS-REF-MAVA-0025. Princeton, NJ: Bristol-Myers Squibb; 2022.
  10. Ho CY, Day SM, Ashley EA, et al. Genotype and lifetime burden of disease in hypertrophic cardiomyopathy: insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe). Circulation. 2018;138(14):1387-1398. doi:10.1161/CIRCULATIONAHA.117.033200
  11. Rowin EJ, Maron MS, Chan RH, et al. Interaction of adverse disease related pathways in hypertrophic cardiomyopathy. Am J Cardiol. 2017;120(12):2256-2264.
  12. MacIntyre C, Lakdawala NK. Management of atrial fibrillation in hypertrophic cardiomyopathy. Circulation. 2016;133(19):1901-1905.
  13. Maron BJ, Olivotto I, Bellone P, et al. Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2002;39(2):301-307.
  14. Palandri C, Santini L, Argirò A, et al. Pharmacological management of hypertrophic cardiomyopathy: from bench to bedside. Drugs. 2022;82(8):889-912. doi:10.1007/s40265-022-01728-w
  15. CAMZYOS [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2023.
3500-US-2300704 12/23